Why the NANOPULSE-AF enrollment milestone matters for Pulse Biosciences
Pulse Biosciences (PLSE) has hit full enrollment in its pivotal NANOPULSE-AF Study, reaching 164 evaluable patients across 15 sites, a key step in evaluating its nPulse Cardiac Catheter System.
Recent price action has been strong, with a 90.11% 3 month share price return and a 273.26% year to date share price return that coincide with milestones such as NANOPULSE-AF enrollment and nPulse technology presentations. Over longer horizons, total shareholder return has been very large, including a 1 year gain of 159.64% and a 3 year increase of more than 11x. Investors are likely to compare this momentum against Pulse Biosciences' clinical and commercial execution from here.
Spot similar high-momentum medical technology stories by scanning our hand picked 32 healthcare AI stocks, which are also pushing new procedures and devices toward broader clinical use.After a move like Pulse Biosciences has just posted, the fork in the road is clear. Are buyers still being paid enough for the clinical and valuation risk on the table?
Most Popular Narrative: 7% Undervalued
Pulse Biosciences last closed at $49.98, while the most followed fair value framework sits at $54.00. The current price sits slightly below that narrative estimate and places more emphasis on how the clinical story develops than on near term financials.
Advancing clinical programs for the nPulse cardiac surgical clamp and nPulse 360 Catheter in atrial fibrillation, including FDA IDE approval, breakthrough designation, and expanding EU feasibility data, creates a path to entry in a high value EP and cardiac surgery market that can expand the company’s addressable revenue base and long term earnings power.
See why 2 investors see Pulse Biosciences as 7% undervalued.
Result: Fair Value of $54 (UNDERVALUED)
Still, the Pulse Biosciences story leans heavily on unproven clinical programs and very high implied future P/E assumptions that could reset quickly if trials or regulators disappoint.
Find out about the key risks to this Pulse Biosciences narrative.
Another View on Pulse Biosciences valuation
There is a sharp contrast once the SWS DCF model is brought into the picture. At $49.98, Pulse Biosciences trades well above an estimated future cash flow value of $16.52. This screens as overvalued on this framework and raises a simple question: is the market paying far more for story than for cash flows?
For readers who want to see how this cash flow driven view is built line by line, the next step is to review how the SWS DCF model works in practice, then judge whether the inputs look realistic for Pulse Biosciences. Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Pulse Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 27 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed signals on Pulse Biosciences so far. If you want to move quickly and build your own stance, start by weighing its 1 key reward and 2 important warning signs.
Looking for more investment ideas beyond Pulse Biosciences?
If Pulse Biosciences has your attention, do not leave your next move to guesswork. Use data driven shortlists to pressure test your instincts and uncover fresh possibilities.
- Expand your opportunity set by reviewing a curated 20 high quality undiscovered gems that pair strong fundamentals with under-the-radar stories the broader market may be overlooking.
- Strengthen your downside protection by focusing on a list of solid balance sheet and fundamentals (25 results) that can help you avoid fragile businesses when conditions get tougher.
- Lock in potential income streams by scanning a 8 dividend fortresses that screens for higher yielding payouts with an eye on sustainability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com